Spring Bank Pharmaceuticals, Inc. (SBPH) financial statements (2020 and earlier)

Company profile

Business Address 35 PARKWOOD DRIVE
HOPKINTON, MA 01748
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments54485125
Cash and cash equivalents29152411
Short-term investments26332714
Other undisclosed current assets4211
Total current assets:58495126
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment2211
Long-term investments and receivables 17 1
Long-term investments 17 1
Restricted cash and investments000 
Other noncurrent assets0000
Total noncurrent assets:52011
TOTAL ASSETS:63695227
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5444
Accounts payable2222
Accrued liabilities2232
Interest and dividends payable0   
Debt0   
Total current liabilities:5444
Noncurrent Liabilities
Long-term debt and lease obligation3   
Operating lease, liability3
Liabilities, other than long-term debt0000
Other liabilities0000
Other undisclosed noncurrent liabilities199136
Total noncurrent liabilities:229136
Total liabilities:28131810
Stockholders' equity
Stockholders' equity attributable to parent36563517
Common stock0000
Additional paid in capital16215811469
Accumulated other comprehensive loss(0)(0)(0)(0)
Accumulated deficit(126)(102)(79)(52)
Total stockholders' equity:36563517
TOTAL LIABILITIES AND EQUITY:63695227

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Gross profit:   0
Operating expenses(33)(28)(21)(20)
Operating loss:(33)(28)(21)(19)
Nonoperating income
(Investment Income, Nonoperating)
1100
Interest and debt expense(1)   
Loss before gain (loss) on sale of properties:(32)(27)(21)(19)
Other undisclosed net income85  
Net loss:(24)(23)(21)(19)
Other undisclosed net income (loss) attributable to parent  (7)2
Net loss attributable to parent:(24)(23)(28)(17)
Other undisclosed net loss available to common stockholders, basic (5)  
Net loss available to common stockholders, diluted:(24)(27)(28)(17)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(24)(23)(21)(19)
Comprehensive loss:(24)(23)(21)(19)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(7)2
Comprehensive loss, net of tax, attributable to parent:(24)(23)(28)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: